Lack of B7 expression, not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas

被引:29
作者
Anderson, Richard C. E.
Anderson, David E.
Elder, James B.
Brown, Melandee D.
Mandigo, Christopher E.
Parsa, Andrew T.
Goodman, Robert R.
McKhann, Guy M.
Sisti, Michael B.
Bruce, Jeffrey N.
机构
[1] Columbia Univ Coll Phys & Surg, Gabriele Bartoli Brain Tumor Res Lab, Dept Neurol Surg, Neurol Inst, New York, NY 10032 USA
[2] Brigham & Womens Hosp, Ctr Neurol Dis, Dept Neurol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, San Francisco, CA 94143 USA
关键词
B7; costimulation; glioma; human leukocyte antigen;
D O I
10.1227/01.NEU.0000255460.91892.44
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Lack of human leukocyte antigens and costimulatory molecules have been suggested as mechanisms by which human malignant gliomas avoid immune recognition and elimination. Methods: Using quantitative multiparameter flow cytometric analysis, tumor cells from patients with glioblastoma multiforme (n = 18) were examined ex vivo for the expression of human leukocyte antigen Class I and 11 molecules and the costimulatory molecules B7-1 and B7-2. They were compared with reactive astrocytes; from peritumoral brain metastases (n = 7), and astrocytes removed during nontumor surgery (n = 5). Results: In contrast to the vast majority of solid peripheral human tumors, these results demonstrate that glioblastorna multiforme frequently express both human leukocyte antigen Class I and II molecules. Like most solid peripheral tumors, glioblastorna multiforme tumor cells express few or no 137 costimulatory molecules. Functional assays using heterogeneous ex vivo tumor preparations or pure populations of ex vivo tumor cells and microglia obtained using fluorescence-activated cell sorting indicate that CD4(+) T-cells are activated by tumor cells only in the presence of exogenous 137 costimulation (provided by addition of soluble agonist anti-CD28 monoclonal antibody). Conclusion: Thus, in contrast to many solid peripheral tumors, failure to present tumor antigens is not a likely impediment to immunotherapeutic strategies against malignant gliomas. Rather, immunotherapeutic strategies need to overcome low levels of 137 costimulation.
引用
收藏
页码:1129 / 1136
页数:8
相关论文
共 37 条
[1]   Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population [J].
Anderson, DE ;
Bieganowska, KD ;
Bar-Or, A ;
Oliveira, EML ;
Carreno, B ;
Collins, M ;
Hafler, DA .
NATURE MEDICINE, 2000, 6 (02) :211-214
[2]   Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro [J].
Anderson, RC ;
Elder, JB ;
Brown, MD ;
Mandigo, CE ;
Parsa, AT ;
Kim, PD ;
Senatus, P ;
Anderson, DE ;
Bruce, JN .
CLINICAL IMMUNOLOGY, 2002, 102 (01) :84-95
[3]   RELATIONSHIP OF LYMPHOCYTE INVASION AND SURVIVAL OF BRAIN TUMOR PATIENTS [J].
BROOKS, WH ;
MARKESBERY, WR ;
GUPTA, GD ;
ROSZMAN, TL .
ANNALS OF NEUROLOGY, 1978, 4 (03) :219-224
[4]   Current and future strategies for the treatment of malignant brain tumors [J].
Castro, MG ;
Cowen, R ;
Williamson, IK ;
David, A ;
Jimenez-Dalmaroni, MJ ;
Yuan, X ;
Bigliari, A ;
Williams, JC ;
Hu, J ;
Lowenstein, PR .
PHARMACOLOGY & THERAPEUTICS, 2003, 98 (01) :71-108
[5]   Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity [J].
Chen, LP .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (05) :336-347
[6]  
Debinski W, 1998, CRIT REV ONCOGENESIS, V9, P255
[7]   Immune defects observed in patients with primary malignant brain tumors [J].
Dix, AR ;
Brooks, WH ;
Roszman, TL ;
Morford, LA .
JOURNAL OF NEUROIMMUNOLOGY, 1999, 100 (1-2) :216-232
[8]   The immunobiology of cancer immunosurveillance and immunoediting [J].
Dunn, GP ;
Old, LJ ;
Schreiber, RD .
IMMUNITY, 2004, 21 (02) :137-148
[9]   Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors [J].
Facoetti, A ;
Nano, R ;
Zelini, P ;
Morbini, P ;
Benericetti, E ;
Ceroni, M ;
Campoli, M ;
Ferrone, S .
CLINICAL CANCER RESEARCH, 2005, 11 (23) :8304-8311
[10]   MHC class I antigens, immune surveillance, and tumor immune escape [J].
Garcia-Lora, A ;
Algarra, I ;
Garrido, F .
JOURNAL OF CELLULAR PHYSIOLOGY, 2003, 195 (03) :346-355